



Psychedelics company Havn Life announces commencement of public trading on the CSE

*Havn Life Sciences will trade on the CSE under the Ticker Symbol HAVN*

## **September 8, 2020**

**Vancouver, BC - Havn Life Sciences Inc. (CSE : [HAVN](#))** (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has commenced trading on the Canadian Securities Exchange ("CSE") under the ticker symbol "HAVN".

"Listing on the Canadian Securities Exchange is an important step in Havn Life's growth within the emerging global psychedelic space," says Tim Moore, Havn Life Co-CEO. "There is a tremendous opportunity to transform and enhance the healthcare and wellness space with psychedelic medicine, and the time is now to lay the foundations for what is likely to be a significant industry. Our multidisciplinary team is focused on laying the groundwork by developing quality controls and methodology for research and the medical supply chain."

Havn Life is focused on the standardized, quality-controlled extraction of psychoactive compounds from plants and fungi to develop products for use in research.

Havn Life is also developing natural healthcare products designed to unlock human potential, containing novel and natural psychoactive compounds.

"We are currently working on a variety of projects including product formulation of effective microdosing of novel psychoactive compounds as well as the development of a state-of-the-art mycology lab for extraction," said Susan Chapelle, Co-CEO of Havn Life.

### **The Team:**

Havn Life boasts a multidisciplinary board with deep experience in pharmaceuticals, technology and cannabis, including directors Rick Brar and Tim Laidler; executive co-chairs Robert Nygren and Barinder Rasode.

Co-CEO, Tim Moore, has championed start-ups and acquisitions with small and large organizations. Tim has over 30 years' experience in Fortune 500 leadership roles in both Canada and the U.S. He formerly served as CEO of Green Growth Brands, a U.S. multi-state cannabis company that operated over 200 mall-based CBD kiosks and following its IPO, reached a peak valuation of over \$1.2 billion dollars.

Co-CEO, Susan Chapelle, formerly served as a civic politician and is a recognized leader in the Canadian cannabis space, having consulted with senior levels of government. She brings 25



years of leadership experience as a researcher, as well as in the health, technology, non-profit, and private sectors in Canada.

Dr. Ivan Casselman (Ph.D., FLS) serves as Havn Life's Chief Psychedelic Officer. Dr. Casselman is an experienced formulation chemist with a strong foundation in nutraceutical formulation and product development. He has led design teams that have produced several retail cannabis products for the Canadian and US markets.

Chief Scientific Officer, Gary Leong served as the CSO at [Jamieson Laboratories](#) in Windsor, Ontario for 14 years, and the CSO at Aphria Inc. for five years. Mr. Leong has a thorough and deep-rooted knowledge of formulation development and the Natural Health Products market.

Vic Neufeld serves as a director on the Havn Life board of directors. Mr. Neufeld was previously the CEO of Jamieson Laboratories for 21 years, Canada's largest manufacturer and distributor of natural vitamins and minerals. He led the Company from \$20 million in annual sales to over \$250 million and expanded the company's distribution network to over 40 countries.

The Havn Advisory Board consists of the Honourable Sheila Copps, David Mokler and Allen Oberman. The honourable Sheila Copps was the first woman to ever hold the position of Deputy Prime Minister and served for 10 years in the federal cabinet of the Canadian Government. David Mokler who is a neuropharmacology, psychopharmacology, substance abuse, drug abuse, brain development, dopamine and serotonin including work relevant to the 5HT2a receptors in psychedelics. As well as, Allen Oberman whom served as the CEO of Concordia International, an international speciality pharmaceutical company with sales in 90 countries and over 200 medicines.

Others on the management team include Chief Research Officer, Alexzander Samuelsson, Chief Financial Officer, Eli Dusenbury, and Director of Innovation and Quality Assurance, Juliana Mollica.

The Company is engaged in an agreement with Skanderbeg Capital Advisors Inc. of Vancouver to provide capital market advisory services and corporate communications including introductions to prospective investors and merger and acquisition transactions and advising on capital structuring and other financial aspects of financings or strategic transactions.

### **On Behalf of The Board of Directors**

Susan Chapelle & Tim Moore  
Co-CEOs

### **About Havn Life Sciences Inc.**

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: [havnlife.com](http://havnlife.com) and follow us on [Facebook](#), [Twitter](#) and [Instagram](#).



**Contact:**

Investor Relations: [ir@havnlife.com](mailto:ir@havnlife.com) 604 359 0060

Media: [brittany@exvera.com](mailto:brittany@exvera.com) 778 238 6096

**Forward-Looking Information:** *This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.*

**The CSE has not reviewed, approved or disapproved the content of this press release**

